PHAT
Phathom Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.01
+1.30%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$6.88
From 52W high−61.23%
Volume1.02M
Market cap$567.12M
P/E (TTM)—
P/S (TTM)2.4x
Div yield—
Key dataOct 19, 2026
Open
$6.88
From 52W high
−61.23%
Volume
1.02M
Market cap
$567.12M
ValuationView details →
P/E (Fwd)
20.5x
EV/EBITDA
−15.7x
P/E (TTM)
—
RSI (14)
40.7
MomentumView details →
1D Return
+1.30%
YTD Return
−58.11%
SummaryUpdated Jun 1, 2026
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Florham Park, New Jersey. The company went public in October 2019 and focuses on developing and commercializing novel treatments for gastrointestinal diseases. Phathom's primary asset is <b>VOQUEZNA</b> (vonoprazan), a potassium-competitive acid blocker that represents a new class of acid-suppressing medications for treating stomach acid-related conditions. The company has successfully launched VOQUEZNA in the United States and is working to expand its commercial footprint while developing additional indications for the drug.
Similar companies
Latest newsMore news →
Phathom Pharmaceuticals announced that it will present three analyses of VOQUEZNA at the American College of Gastroenterology 2026 Annual Scientific Meeting, covering real-world patient characteristics, efficacy across BMI subgroups and cost-effectiveness in erosive esophagitis.12d agoPhathom Pharmaceuticals initiated patient screening in the registrational Phase 3 pHalcon-NERD-302 study evaluating as-needed VOQUEZNA (vonoprazan) tablets in adults with Non-Erosive GERD.21d ago